NCT04293562 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT04293562
Title	A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Children's Oncology Group
Indications	acute myeloid leukemia
Therapies	Cytarabine + Daunorubicin + Hydrocortisone + Methotrexate Cytarabine + Etoposide + Hydrocortisone + Methotrexate Cytarabine + Hydrocortisone + Methotrexate + Mitoxantrone Cytarabine + Daunorubicin + Gemtuzumab ozogamicin + Gilteritinib + Hydrocortisone + Methotrexate Cytarabine + Daunorubicin + Gemtuzumab ozogamicin + Hydrocortisone + Methotrexate Gilteritinib Asparaginase Erwinia chrysanthemi + Cytarabine Cytarabine + Daunorubicin + Gilteritinib + Hydrocortisone + Methotrexate Cytarabine + Etoposide + Gilteritinib + Hydrocortisone + Methotrexate Cytarabine + Gilteritinib + Hydrocortisone + Methotrexate + Mitoxantrone Asparaginase Erwinia chrysanthemi + Cytarabine + Gilteritinib
Age Groups:	child \| adult
Covered Countries	USA \| CAN \| AUS

Additional content available in CKB BOOST